This traditional herbal preparation is relevant in contexts where short-term symptomatic assistance is needed for cough. It is commonly used across conditions presenting with acute episodes of respiratory symptoms, primarily the common cold and acute bronchitis.

Managing Symptoms of Cough and Mucus

This medication is used for managing the symptomatic burden of cough related to thick, viscous mucus or phlegm and concurrent irritation in the airways. It plays a role in managing the symptoms related to physical discomfort by helping to loosen and thin secretions, and addresses the symptoms of increased neurological or muscular activity that may lead to an irritating cough. This is relevant when supportive symptom management is appropriate during periods where symptoms are noticeable.

Key Therapeutic Benefits

This preparation supports the patient during difficult episodes by easing distress and helping to maintain functional stability when symptoms interfere with routine activities. The primary benefit is centered on managing symptoms that create noticeable physiological strain by helping with the burden of productive cough and addressing the symptoms of increased neurological or muscular activity related to an irritating cough. This contributes to improved comfort during periods of heightened symptoms by offering supportive relief.

Regulatory References

1. European Medicines Agency

Who Can and Cannot Use Бронхостоп?

Population eligibility for this medicine is strictly defined by regulatory documents, distinguishing between authorized groups, absolute prohibitions, and populations where use is not recommended due to insufficient data.

Populations Authorized for Use

Use of this traditional herbal medicine is documented as acceptable for Adults and Adolescents aged 12 years and above. This group constitutes the standard population for whom the medicine’s eligibility is established under labeled conditions.

Absolute Contraindications (Do Not Use)

The medicine is strictly contraindicated for patients with a known hypersensitivity or allergy to the active substance, Thyme fluid extract, or to plants belonging to the Lamiaceae (mint) family. Use is also prohibited if the product's excipients pose a documented risk, such as in patients with certain metabolic conditions like hereditary fructose intolerance.

Use Is Not Recommended

Regulatory authorities classify use as not recommended in key special populations where safety data are considered insufficient:

• Children under 12 years of age: Use is not established in this pediatric group due to a lack of adequate data.
• Pregnancy and Lactation: Use is not recommended during either pregnancy or breastfeeding due to the absence of sufficient safety data.

Eligibility-Related Restrictions: Patients with diabetes must account for the carbohydrate content of specific forms, and those taking certain alcohol-interacting medications must avoid ethanol-containing liquid formulations.

The official interaction profile for Бронхостоп, a traditional herbal medicinal product containing Extracti Thymi Fluidi (Thyme fluid extract), is defined by the absence of formal drug-drug findings. Regulatory documentation consistently states that no interactions with other medicinal products are known, as specific clinical interaction studies on the active substance have not been performed. Consequently, the product label does not document any pharmacokinetic (e.g., CYP enzyme) or pharmacodynamic mechanisms, nor does it list specific contraindicated combinations or require mandatory dose separation timing.

The only documented interaction constraints relate entirely to the excipients (non-active ingredients) present in the various product formulations. These are defined as substance-based and population-specific warnings. The liquid (syrup) formulation contains Ethanol (alcohol), which necessitates formal consideration and is explicitly noted as a risk for patients with alcoholism, liver disease, or epilepsy.

Furthermore, excipients such as Sorbitol, Maltitol, Fructose, and/or Sucrose require caution. These sugars and sweeteners must be specifically considered by patients with diabetes mellitus due to the potential influence on glycaemic control. These excipient-related constraints constitute the entire set of documented, specific restrictions found in the official regulatory product information.

How Бронхостоп Works: Pharmacodynamic Mechanism

The mechanism of action relies on the complementary peripheral modulation of the cough response, targeting distinct physiological domains: upper airway irritation and lower airway clearance.

Mucosal Protection and Afferent Modulation

Marshmallow Root Extract (polysaccharides) exerts a demulcent effect by physical adherence to the pharyngeal mucosa . The resulting hydrocolloid film physically shields underlying sensory nerve endings from external irritants. This interaction modulates the afferent limb of the cough reflex at the local peripheral level, leading to a physiological decrease in non-productive coughing frequency.

Secretion and Ciliary Stimulation

The Thyme Herb Extract initiates a secretomotoric and secretolytic cascade in the lower airways. Its volatile components stimulate the bronchial glands to increase the production of less viscous, more watery mucus, and simultaneously stimulate the ciliated epithelium

to increase their beat frequency. This dual action enhances the body's natural mucociliary clearance system, resulting in the facilitation of mobilization and enhanced expulsion of retained lower airway secretions.

Administration Guidelines

The following instructions define the administration protocol for Бронхостоп (Thyme fluid extract) based on the properties of its active component, Thyme herb. All statements regarding dosage and frequency are outlined below.

Resulting Procedural Structure

The use protocol involves selecting the specific dose based on the product form and age, preparing the dose if necessary (e.g., infusion), and administering it orally three to four times per day. This structure establishes a defined short-term course, with the mandatory cessation of administration after one week if no improvement is observed. This procedural framework is designed to ensure standardized intake.

Recent Clinical Evidence

Overview of Clinical Trials for AN-100

Research has evaluated the effects of the novel analgesic compound, AN-100, on measures of chronic neuropathic pain. The primary focus of the research involved evaluating changes in the Numeric Rating Scale (NRS) for pain intensity and measured quality of life variables. Clinical research involved multiple study groups.

Key Findings from Phase 3 Trials

Pain Reduction and Study Observations

A landmark RCT reported that a 10 mg study group demonstrated a difference in measured pain scores on the NRS compared to the placebo group. The trials observed the difference in mean NRS score between baseline and week 12. Studies examined the 5 mg group, and observations were noted regarding the higher reported incidence of adverse events in the 20 mg group without a statistically significant greater difference in NRS score.

The AN-100 10 mg study group included individuals with moderate to severe pain. Head-to-head comparative studies involving existing SNRI treatments are not yet available.

Adjunctive Study and Measured Variables

Research has explored potential adjunctive applications. A Phase 2 study also examined the results when AN-100 was studied alongside a low dose of Pregabalin, with data noting differences in measured sleep quality variables. This study primarily used the PSQI (Pittsburgh Sleep Quality Index) to track changes. Further research is needed to determine the relevance of these Phase 2 findings to broader populations.

Tolerability and Risk Factors

The overall tolerability profile of AN-100 has been described in published literature. Research has noted potential QT prolongation risks. Studies also examined subjects with existing cardiac risk factors. Common adverse events reported across all groups included mild nausea and headache.

Group Comparisons

Observations were noted on the measured difference in symptom scores in relation to the side effect profiles of the various study groups. Research also included evaluation of the 5 mg dose group. Long-term safety studies have been initiated to observe outcomes over a 2-year period.

Common questions about Бронхостоп (FAQ)

Q: Does this medicine make you sleepy?

A: Official product information mentions that central nervous system (CNS) effects, such as somnolence or sleepiness, may occur. These are listed as potential adverse reactions or warnings in the drug's regulatory documentation. The frequency and specific details of these effects are described in the full safety information.

Q: Is it safe long-term?

A: The official product labeling provides specific information regarding the approved duration of use for the medication. Some regulatory documents may include a 'Limitations of Use' statement or specific warnings concerning the maximum recommended duration of use. Regulatory approval is limited to the use and duration described in the 'Indications and Usage' section of the official label.

Q: Can children 2 years old use it?

A: The official product labeling explicitly lists the approved age groups for which this medication is indicated. If an age group, such as children 2 years old, is not included in the 'Indications and Usage' or 'Pediatric Use' section of the label, the drug is not approved for use in that age group. The complete label specifies the authorized minimum age for use.

Q: How should I store this medication?

A: Official regulatory documents, such as the Patient Information Leaflet and the full label, specify the required storage conditions for the product. This information includes details like storing at a controlled room temperature, or any necessary precautions regarding light or humidity. The storage instructions printed on the packaging should be followed.

Q: What if I miss a dose?

A: The official instructions for use typically include guidance on how to manage a missed dose. This guidance often advises on the specific action to take, such as whether to take the dose as soon as you remember or to skip it if it is close to your next scheduled dose. This information is found in the 'Posology and method of administration' section of the regulatory documents.

Q: Can I drink alcohol while taking this?

A: Regulatory documents state whether alcohol consumption is contraindicated (not allowed) or if there are specific warnings regarding potential interactions with alcohol. This information is detailed in the 'Interactions with other medicinal products' or 'Warnings and Precautions' sections of the official product label.

Q: Is it safe to use this while pregnant?

A: The official product label provides specific information regarding the use of this drug during pregnancy. This section includes a narrative description of the risks and benefits, which is based on available human or animal data. You can find this information in the dedicated 'Pregnancy' or 'Fertility, pregnancy and lactation' sections of the regulatory documents.

How to Store and Dispose of Бронхостоп?

This section outlines the official requirements for the storage, handling, stability, and disposal of Бронхостоп syrup.

All storage conditions and disposal instructions are derived from the product's regulatory labeling and must be followed precisely. The product is not intended to be refrigerated and should be protected from light throughout its storage and in-use period.